

and which Application was the Application entering the National Phase in the United States from PCT Application Serial No. PCT/CA90/00306^{filed 9-18-90} which Application claims priority from Canadian Patent Application Serial No. 612,307-4 filed September 21, 1989."

In the Response also dated March 5, 1993 to the Official Action relating to the Election of Inventions, the Applicants enclosed two documents, each entitled "Declaration, Power of Attorney, and Petition" executed by Drs. Rudolf Edgar Falk and Samuel Simon Asculai which referred to the Canadian Patent Application Serial No. 2,061,566 from which Applicants claimed convention priority and referred in the said Declaration, Power of Attorney, and Petition to the earlier filed United States Patent Application 07/675,908 from which it claimed the Application was a Continuation-In-Part Application. (Applicants also enclosed a certified copy of Canadian Application 2,061,566 from which priority was claimed.) The Examiner now states in paragraph 17 of the Action that the Oaths or Déclarations are defective. Applicants are in the process of preparing a new Oath and Delcaration as a single Oath or Declaration and will be forwarding same in due course.

IN THE CLAIMS

Please amend the claims as follows:

6. (Thrice Amended) A method of treating a disease or condition of the skin and exposed tissue comprising, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata), cervical cancer, and HPV